Bengaluru-based deeptech healthcare startup Morphle Labs has raised $5 Mn (INR 44.6 Cr) in its Series A round led by Inflexor Ventures, as it looks to strengthen its technology stack and accelerate global expansion.
The company plans to use the fresh funds to ramp up manufacturing for its flagship diagnostic automation products — RoboTome and MorphoLens — while also pursuing regulatory approvals and expanding its engineering and research teams.
Founded in 2017 by Rohit Hiwale and Anchit Navelkar, Morphle Labs builds robotics- and AI-driven systems to automate tissue diagnostics, using advanced optics, precision hardware, and imaging technologies. The startup says it has filed more than 80 patents across robotics, optics, embedded systems, and imaging innovations.
Automating pathology workflows
Morphle’s flagship product RoboTome automates the slicing of tissue blocks into ultra-thin sections for microscope slides — a critical step in cancer diagnosis. By standardising slide quality, the device helps pathologists achieve faster and more accurate results.
The startup’s second major product, MorphoLens, functions as a digital slide scanner that enables detailed imaging for cellular-level examination. Doctors and trained technicians use the tool to detect subtle tissue abnormalities that may indicate disease.
Morphle Labs is also developing HemoLabs, a solution designed to automatically locate blood cells and platelet fragments for analysis, streamlining hematology workflows.
The company is currently expanding its commercial presence in the US and Europe, strengthening its position in the growing global market for automated diagnostics.
Deeptech healthcare funding gains momentum
Morphle Labs’ raise adds to a recent wave of early-stage funding in India’s deeptech healthcare sector. In November, biotech startup Helex secured $3.5 Mn to advance pre-clinical development of its lead program focused on treating Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Meanwhile, Avammune Therapeutics raised $12 Mn to scale its ENPP1 inhibitor research and accelerate clinical development of new drug candidates.
With rising demand for automated, accurate, and scalable diagnostic solutions, startups like Morphle Labs are positioning themselves at the forefront of healthcare innovation.